TSVT 2seventy bio Quarterly EPS earnings growth

2seventy bio, Inc. (TSVT) attracts top engineers through innovations in CAR-T therapy, offering them autonomy and RSUs. Quarterly EPS growth illustrates the profitability trend, where this metric equals 100.80. However, trade wars and sanctions are hindering the global exchange of medical technologies. The business is currently focusing on the market rollout of Abecma and the optimization of its scientific portfolio to combat oncology.

2seventy bio (TSVT) Year-over-year earnings per share growth for the last twelve months: for the period 07/04/2022 - 05/24/2025

2seventy bio, Inc (TSVT) - metric breakdowns and financial figures

- share price and expert price forecast:

Stock Price 2seventy bio|TSVT - Consensus Target

- market capitalization data:

Market Capitalization 2seventy Bio|TSVT - Total Enterprise Value

- balance sheet net asset value indicators:

Net Assets per Single Share 2seventy bio|TSVT - Company Book Value|Market Value to Book Value Ratio 2seventybio.com|TSVT - Aggregate Company Assets

- company liabilities and liquidity data:

- earnings and market multiples details:

TSVT - Company Net Income|Future Profit 2seventy bio, Inc.|TSVT - Company Value to Net Income|Projected Price to Earnings 2seventy Bio|TSVT - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple 2seventy Bio|TSVT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) 2seventy bio|TSVT - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months 2seventybio.com|TSVT - Earnings per share increase in current year|Earnings growth forecast for next year 2seventy bio, Inc.

- sales volume and revenue information:

TSVT - Revenue and Sales Volume|Company Projected Revenue 2seventy bio|TSVT - Price-to-Sales Ratio|Forward Price-to-Revenue Multiple 2seventy Bio

Fundamental company analysis:2seventy bio - TSVT

The specifics of 2seventy bio, Inc. (TSVT) gene therapy amid geopolitical risks and logistical disruptions make the quarterly EPS growth rate a key indicator of the business's operational resilience. This metric measures the rate of change in net income per share relative to the previous quarter, allowing investors to assess the actual efficiency of asset capitalization and the company's long-term ability to generate income.

Analysis of competing companies

LEGN: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Sana Biotechnology Inc|AUTL (Autolus Pharma) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Allogene Corp ALLO|Year-over-year earnings per share growth for the last twelve months Cartesian Therapeutics (RNAC)|Year-over-year earnings per share growth for the last twelve months CLLS (cellectis.com)|Year-over-year earnings per share growth for the last twelve months Caribou Biosciences, Inc. CRBU|Instil Bio Inc. - Year-over-year earnings per share growth for the last twelve months|GNTA: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months IPSC (Century Therapeutics)|JSPR: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Senti Biosciences SNTI|ADAP (Adaptimmune Therapeutics plc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months CERo Therapeutics Holdings Inc. CERO|Year-over-year earnings per share growth for the last twelve months Alaunos Therapeutics (TCRT)|achillestx.com - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth CRGX (CARGO Therapeutics)|poseida.com (PSTX) - Earnings per share growth in annualized terms for the last twelve months|GRCL: Year-over-year net earnings per share growth for the last 12 months